Evidence map›Paper›PMID 30269490›Full record

ReviewACS chemical neuroscience2018

DARK Classics in Chemical Neuroscience: Aminorex Analogues.

Julian Maier, Felix P Mayer, Simon D Brandt, Harald H Sitte

Open access · greenAbstract readHistorical ArticleReview
In one paragraph

Review in ACS chemical neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. 4,4'-DMARFrontiers in cardiovascular medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Worsening of the Toxic Effects of (±)International journal of molecular sciences · 2021
    Article
  6. Review
  7. Review
  8. Interpol review of controlled substances 2016-2019.Forensic science international. Synergy · 2020
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Julian MaierCenter for Physiology and Pharmacology, Institute of Pharmacology , Medical University of Vienna , Währingerstraße 13A , 1090 Vienna , Austria.
Felix P MayerCenter for Physiology and Pharmacology, Institute of Pharmacology , Medical University of Vienna , Währingerstraße 13A , 1090 Vienna , Austria.
Simon D BrandtSchool of Pharmacy and Biomolecular Sciences , Liverpool John Moores University , Byrom Street , Liverpool L3 3AF , United Kingdom.
Harald H SitteCenter for Physiology and Pharmacology, Institute of Pharmacology , Medical University of Vienna , Währingerstraße 13A , 1090 Vienna , Austria.ORCID 0000-0002-1339-7444
Medical University of Vienna · ATLiverpool John Moores University · GB

Funding

Austrian Science Fund FWF W 1232
6 · The paper itself

Abstract

Aminorex (5-phenyl-4,5-dihydro-1,3-oxazol-2-amine) and 4-methylaminorex (4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine) are psychostimulants that have long been listed in Schedules IV and I of the UN Convention on Psychotropic Substances of 1971. However, a range of psychoactive analogues exist that are not internationally controlled and therefore often classified as new psychoactive substances (NPS). Aminorex analogues encompass failed pharmaceuticals that reemerged as drugs of abuse, and newly synthesized substances that were solely designed for recreational use by clandestine chemists. NPS, sometimes also referred to as "designer drugs" in alignment with a phenomenon arising in the early 1980s, serve as alternatives to controlled drugs. Aminorex and its derivatives interact with monoaminergic neurotransmission by interfering with the function of monoamine transporters. Hence, these compounds share pharmacological and neurochemical similarities with amphetamines and cocaine. The consumption of aminorex, 4-methylaminorex and 4,4'-dimethylaminorex (4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine) has been associated with adverse events including death, bestowing an inglorious fame on aminorex-derived drugs. In this Review, a historical background is presented, as well as an account of the pharmacodynamic and pharmacokinetic properties of aminorex and various analogues. Light is shed on their misuse as drug adulterants of well-established drugs on the market. This Review not only provides a detailed overview of an abused substance-class, but also emphasizes the darkest aspect of the NPS market, i.e., deleterious side effects that arise from the ingestion of certain NPS, as knowledge of the pharmacology, the potency, or the identity of the active ingredients remains obscure to NPS users.

Indexed as

Designer DrugsAminorexCentral Nervous System StimulantsHistory, 20th CenturyHistory, 21st CenturyHumansAminorexCentral Nervous System StimulantsDesigner Drugsaminorexdrug abuselevamisolemonoamine transportersnew psychoactive substancesPsychostimulants

Identifiers

PMID30269490
PMCPMC6287711
OpenAlexW2895533370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.